Quote | Nervgen Pharma Corp. (TSXVC:NGEN:CC)
Last: | $2.24 |
---|---|
Change Percent: | -6.67% |
Open: | $2.34 |
Close: | $2.24 |
High: | $2.4 |
Low: | $2.24 |
Volume: | 40,579 |
Last Trade Date Time: | 05/06/2022 04:56:09 pm |
News | Nervgen Pharma Corp. (TSXVC:NGEN:CC)
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Message Board Posts | Nervgen Pharma Corp. (TSXVC:NGEN:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Nervgen Pharma Corp. Company Name:
NGEN:CC Stock Symbol:
TSXVC Market:
Nervgen Pharma Corp. Website:
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...